Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Blood (2016) 128 (5): 686–698.

https://doi.org/10.1182/blood-2016-01-693879

Published: 2016

Includes: Supplemental data

Journal Articles

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Nikola P Konstandin, Klaus H. Metzeler, MD, Annika Dufour, PhD, Philipp A Greif, MD, Tobias Herold, MD, Bianka Ksienzyk, Stephanie Schneider, Dr. rer. nat., Wolfgang E Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Cristina Sauerland, MSc, Jan Braess, MD, Wolfgang Hiddemann, MD, Stefan K Bohlander, MD, Karsten Spiekermann, MD

Blood (2014) 124 (21): 2385.

https://doi.org/10.1182/blood.V124.21.2385.2385

Published: 2014

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

Journal Articles

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Blood (2014) 124 (8): 1304–1311.

https://doi.org/10.1182/blood-2013-12-540716

Published: 2014

Includes: Supplemental data

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood (2013) 122 (10): 1761–1769.

https://doi.org/10.1182/blood-2013-01-476473

Published: 2013

Includes: Supplemental data

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Klaus H. Metzeler, MD, Nadine Sandhöfer, Tanja Hinrichsen, Evelyn Zellmeier, Bianka Ksienzyk, Annika Dufour, PhD, Stephanie Schneider, PhD, Purvi M. Kakadia, PhD, Philipp A Greif, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Hanns-Georg Klein, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2012) 120 (21): 1379.

https://doi.org/10.1182/blood.V120.21.1379.1379

Published: 2012

Journal Articles

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Max Hubmann, MD, Marion Subklewe, MD, Thomas Köhnke, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Michael Fiegl, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, PhD

Blood (2012) 120 (21): 1404.

https://doi.org/10.1182/blood.V120.21.1404.1404

Published: 2012

Journal Articles

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Karl Peter Hopfner, PhD, Purvi M. Kakadia, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Jan Braess, MD, Michael Heuser, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD, Stefan K Bohlander, MD, Philipp A Greif, MD

Blood (2012) 120 (21): 404.

https://doi.org/10.1182/blood.V120.21.404.404

Published: 2012

Journal Articles

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Nikola P Konstandin, Annika Dufour, PhD, Philipp A Greif, MD, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Stephanie Schneider, PhD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, PhD, Kerstin Trunzer, PhD, Martin Weisser, MD, Stefan K Bohlander, MD

Blood (2012) 120 (21): 2514.

https://doi.org/10.1182/blood.V120.21.2514.2514

Published: 2012

Journal Articles

High expression of lymphoid enhancer-binding factor-1 ( LEF1 ) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia

Klaus H. Metzeler, Bernhard Heilmeier, Katrin E. Edmaier, Vijay P. S. Rawat, Annika Dufour, Konstanze Döhner, Michaela Feuring-Buske, Jan Braess, Karsten Spiekermann, Thomas Büchner, Maria C. Sauerland, Hartmut Döhner, Wolfgang Hiddemann, Stefan K. Bohlander, Richard F. Schlenk, Lars Bullinger, Christian Buske

Blood (2012) 120 (10): 2118–2126.

https://doi.org/10.1182/blood-2012-02-411827

Published: 2012

Includes: Supplemental data

Journal Articles

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Blood (2012) 120 (2): 395–403.

https://doi.org/10.1182/blood-2012-01-403220

Published: 2012

Includes: Supplemental data

Journal Articles

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

Blood (2012) 119 (19): 4383–4386.

https://doi.org/10.1182/blood-2010-12-327072

Published: 2012

Includes: Supplemental data

Journal Articles

High Frequency of GATA2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia with Biallelic CEBPA Mutations Identified by Exome Sequencing

Blood (2011) 118 (21): 72.

https://doi.org/10.1182/blood.V118.21.72.72

Published: 2011

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

NARROW

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

High expression of lymphoid enhancer-binding factor-1 ( LEF1 ) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

High Frequency of GATA2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia with Biallelic CEBPA Mutations Identified by Exome Sequencing

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only